Now let me compile the complete final review.

## Summary

This paper introduces a two-stage framework for PPI candidate ranking: (1) an interpretability-guided retrieval step that uses embedding activations from D-SCRIPT/Topsy-Turvy, guided by predicted contact maps, to measure similarity between candidate proteins and known interactors of a target; and (2) a re-ranking step integrating interaction scores, structural plausibility (pDockQ), functional annotations, and LLM-based semantic similarity. The evaluation uses a prospective design (STRING v11 → v12 temporal split) on 279,568 novel v12 interactions.

## Strengths

- **Prospective evaluation design (STRING v11→v12 temporal split).** The paper correctly identifies that most PPI evaluations are static/retrospective and builds an evaluation that directly measures whether the method anticipates *future* discoveries (Section 5.1, Table 1). This is a genuine methodological advance in how PPI methods should be evaluated.

- **Large-scale evaluation.** The scale — 279,568 novel v12 interactions from a filtered set of ~100k+ proteins — is substantial and demonstrates practical applicability (Section 5.1).

- **Comprehensive re-ranking analysis.** The paper investigates many complementary signals (IS, pDockQ, TF-IDF, token/location/key-term overlap, BioBERT, BioMedRoBERTa, PubMedBERT cross-encoder). Table 2's pairwise comparison provides a systematic view of which signals are complementary, which is useful for practitioners.

- **Biologically well-motivated core idea.** Using known interactors as anchors via embedding similarity guided by interpretable contact maps is grounded in the reasonable assumption that novel interactions of a target should follow similar mechanisms to known ones (Section 4.1).

## Weaknesses

### Major

- **The headline claim of "two orders of magnitude" improvement is unsupported by the data.** The abstract (line 25) and conclusion (lines 278-279) state that the method improves ranking metrics by "two orders of magnitude" (~100×). However, the largest improvement in Table 1 is ~26× (MAP@5: 0.0103 → 0.2714 for D-SCRIPT), which is one order of magnitude (~10¹). MRR improves ~5×, and average rank improves ~2×. A 26× improvement is still strong, but "two orders of magnitude" misrepresents the results and is the paper's most prominent claim. This must be corrected.

- **Missing critical ablation: the proposed method uses known interactors KP(p) as anchors — information the baselines do not have.** D-SCRIPT/Topsy-Turvy/xCAPT5 baselines rank candidates by raw interaction score only, while the proposed method additionally uses the known-interactor set. This conflates two things: (a) the value of *using known interactors at all* and (b) the specific *contact-map-guided active-region mechanism* claimed as the methodological contribution. An ablation comparing the proposed active-region method against a simple baseline of full-embedding cosine similarity to known interactors (without contact-map guidance) is needed to isolate the contribution of the claimed innovation. Without this, readers cannot assess what the novel component actually contributes.

### Minor

- **No statistical uncertainty is reported.** Table 1 reports point estimates without confidence intervals, standard deviations, or significance tests. For early cutoffs (k=5, 10) where counts are small, variance matters. Table 2's pairwise comparisons (e.g., 63.0% vs. 63.6% improvement rate) are presented without any significance assessment, making it impossible to determine which differences are reliable.

- **The re-ranking analysis is confined to top-10 candidates** (Section 4.2: "we focus on the top 10 ranked candidates"). The paper reports 2,280 protein-candidate pairs but does not state what fraction of all novel v12 interactions this represents, nor how many unique target proteins are captured. If the first stage already misses most novel partners at k=10, the re-ranking analysis evaluates signal combination on an already-optimistic subset.

- **The method for identifying active regions is underspecified.** Section 4.1 states the method scans for "maximal contiguous segments of highly activated residues" but never defines the threshold or criterion for "highly activated" — whether it is a percentile, an absolute value, or determined dynamically. This affects reproducibility.

- **The paper acknowledges a limitation for underexplored proteins** (Section 6) but provides no analysis of how performance varies with |KP(p)|. Stratifying results by the number of known interactors (e.g., 1–5, 6–20, 20+) would bound the method's applicability.

### Trivial

None.

## Nice-to-Haves

- Add a BLAST-based baseline (ranking by sequence similarity to known interactors) as a simple computational floor.
- Report the fraction of all novel v12 interactions captured within top-10 of the first stage, and characterize the 2,280 re-ranking pairs by unique protein count.

## Removed Points

These points from the input review were removed with justification:

- **Table 2 misinterpretation (PubMedBERT performance)**: The critic claimed PubMedBERT's performance is not supported, citing values 30.4–48.1%. These values appear in the PubMedBERT ROW (switching *from* PubMedBERT), not the column (switching *to* PubMedBERT). The column values (64.8–79.7%) actually support the paper's claim. Factually wrong — removed.

- **xCAPT5 cherry-picking claim**: The paper acknowledges xCAPT5's strong early precision (P@5 = 0.1943, higher than the proposed method's 0.1924) while noting its MRR is lower. The discussion is balanced. Removed.

- **Missing appendix details (hyperparameters, reproducibility)**: The paper references Appendix A.1 (line 231) for experimental setup. The appendix was stripped by the parser. Per policy, removed.

- **OCR artifacts / formatting criticism**: Parser artifacts, not author errors. Removed per policy.

- **PubMedBERT data leakage concern**: The critic raised concern about the cross-encoder potentially benefiting from seeing candidate protein text profiles in v11. The paper explicitly addresses this with GroupKFold splitting by protein identity and evaluation on disjoint v12 interactions. Kept as too speculative — the paper's handling is reasonable.

- **Missing related works**: Removed per policy — cannot verify existence of unmentioned works.

## Novel Insights

None beyond the paper's own contributions. The input review's concerns are standard methodological issues (missing ablation, claim calibration, uncertainty quantification) rather than novel discoveries about the paper.

## Suggestions

1. Replace "two orders of magnitude" with the actual improvement factors (~5–26×).
2. Add an ablation comparing active-region-guided similarity to full-embedding cosine similarity with known interactors (without contact-map guidance).
3. Add bootstrap confidence intervals to Table 1 and a significance test (e.g., McNemar's) to Table 2.
4. Define the threshold/criterion for "highly activated" residues in Section 4.1.
5. Report the fraction of all novel v12 interactions captured within top-10 of the first stage, and how many unique proteins the 2,280 re-ranking pairs cover.
6. Stratify results by number of known interactors |KP(p)| to characterize failure modes for underexplored proteins.

## Calibration Anchors

| Path | Avg Score | Round | Itemized | Comparison |
|---|---|---|---|---|
| `/home/wg25r/.../itGkF993gz.md` (MAPE-PPI) | 5.67 | R1 | Yes | Similar domain (PPI prediction). Has stronger claimed novelty (+6.49 microenvironment) but more severe weaknesses (-9.13 missing refs). Our paper has less severe weaknesses but also less novel architecture. |
| `/home/wg25r/.../xcMmebCT7s.md` (PPIformer) | 5.80 | R1 | Yes | Similar domain. Stronger contributions (new dataset + architecture + splits) with severe weaknesses (-7.42 novelty, -6.56 baselines). |
| `/home/wg25r/.../eh1fL0zw8o.md` (LLaPA) | 6.00 | R1 | Yes | Similar domain. Stronger results but severe missing-baseline weaknesses (-10.14). Our paper's weaknesses are milder but our strengths are also less exceptional. |
| `/home/wg25r/.../jsQPjIaNNh.md` (ProtIR) | 5.25 | R2 | Yes | Most similar in approach (inter-protein similarity modeling). Has severe weaknesses (-9.87 missing baselines, -9.69 lack of innovation). Our paper's weaknesses are better contained. |
| `/home/wg25r/.../ZkpDdCQUC4.md` (NovoBench) | 4.60 | R2 | No | Dataset paper with ranking tasks. Lower contribution density. |
| `/home/wg25r/.../FZfWQFrdBT.md` (SMP) | 5.50 | R2 | No | Inter-chain contact prediction. Similar score range with moderate weaknesses. |
| `/home/wg25r/.../wCwz1F8qY8.md` (DeepSSInter) | 5.00 | R2 | No | Contact prediction. Mixed reviews (3,3,8,6). |
| `/home/wg25r/.../S2WHlhvFGg.md` (DTI prediction) | 3.00 | R1 | No | Lower-tier DTI paper. Our paper is clearly stronger. |
| `/home/wg25r/.../IEZjjDX0iC.md` (Phage pLMs) | 3.00 | R1 | No | Comparative benchmark paper. Our paper has stronger contributions. |

**Round 1 bracket**: 4.0–6.5. **Narrowing**: Comparing weighted items, our paper's total weighted strength (+11.69) and total weighted weakness (-10.67) yields net +1.02. The PPIformer anchor (5.80) has strong weights (+6.50, +5.01, +4.54) but also severe negatives (-7.42, -6.56) — net roughly zero despite higher absolute scores. Our paper has less extreme weights on both sides, placing it slightly below the 5.67–5.80 PPI papers due to less methodological novelty, but above the 5.25 protein function paper because our weaknesses are better contained. **Final score**: 5.5.

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Accept</decision>